| Trial ID: | L1066 |
| Source ID: | NCT00044720
|
| Associated Drug: |
Rapamune
|
| Title: |
Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Failure|Graft vs Host Disease|Kidney Transplantation
|
| Interventions: |
DRUG: Rapamune
|
| Outcome Measures: |
|
| Sponsor/Collaborators: |
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
484
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose:
|
| Start Date: |
|
| Completion Date: |
2005-07
|
| Results First Posted: |
|
| Last Update Posted: |
2009-08-18
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00044720
|
